IN THE CLAIMS:

Please cancel claim 3 without prejudice or disclaimer.

Please replace claims 1-2 and 4-10 as follows:

1. (Amended) A method of treating cancer comprising administering to a patient in need of such treatment using a subcutaneous mode of administration a harringtonine having the formula



wherein:

- R^1 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or null and

  R^2 is H or OH, or R^1, R^2 form together -O-,

  R^3 = R^4 = OMe or R^3 and R^4 form together -OCH_2O-,
- n is 0 to 8,
- R^5 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or O-aryl,

Z = O, S, or NH, and



or Z-R^8 is $NR^{12}R^{13}$, R^{12} and R^{13} representing respectively R^9 and R^{10},

R^9, R^{10}, R^{11} are independently H, C_1-C_{30} alkyl, C_3-C_{30} cycloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl, C_2-C_{30} alkynyl, C_1-C_{30} trihalogenoalkyl, C_1-C_{30} alkylamino-(C_1-C_{30})alkyl, C_1-C_{30} dialkylamino(C_1-C_{30})-alkyl, amino-(C_1-C_{30})-alkyl,

93
Cont

or



where R^{14}, R^{15}, R^{16} are independently H, halogen, C_1-C_{30} alkyl, C_3-C_{30} cycloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl, C_2-C_{30} alkynyl, or C_1-C_{30} trihalogenoalkyl, and m is 0 to 4,

each of these groups optionally including heteroatom(s),

or salt or tautomeric form thereof.

SUB B1

2. (Amended) The method of claim 1 where the harringtonine is homoharringtonine or harringtonine having the following formula



where n = 1 or 2.

4. (Amended) The method of claim 15 in which the acid which forms a salt of harringtonines is hydrochloric acid or tartaric acid.

SUB B2

5. (Amended) The method of claim 1 in which the harringtonines are solutions or hydrophilic freeze-dried powder ready-to-constitute of buffered salt of homoharringtonine or harringtonine of which the level of chromatographic purity suitable for medical use is higher than 99.7%.

6. (Amended) The method of claim 15 in which the pH of the formulation or constituted solution for injection is between 5.5 and 8.

7. (Amended) The method of claim 1 in which harringtonines are combined with another pharmaceutically acceptable agent in the same injection.

8. (Amended) The method of claim 7 in which the additional agent is a nucleoside.

9. (Amended) The method of therapy of claim 1 in which the subcutaneous mode of administration is performed by bolus injection at regular intervals.

10. (Amended) The method of claim 1 in which the subcutaneous mode of administration is performed by continuous subcutaneous infusion.

Please add new claims 11-27 as follows:

---

11. (New) The method of claim 1, wherein at least one additional antitumor agent is administered with the harringtonine.

12. (New) A method of treating leukemia comprising administering to a patient in need of such treatment using a subcutaneous mode of administration a harringtonine having the formula



wherein:

- R^1 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or null and

  R^2 is H or OH, or R^1, R^2 form together -O-,

  R^3 = R^4 = OMe or R^3 and R^4 form together -OCH_2O-,

- n is 0 to 8,

- R^5 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or O-aryl,

  Z = O, S, or NH, and

$$R^8 = \begin{array}{l} R^9 \\ \diagup \\ -\!\!<\!\!- R^{10} \\ \diagdown \\ R^{11} \end{array}$$

or Z-R^8 is $NR^{12}R^{13}$, R^{12} and R^{13} representing respectively R^9 and R^{10},

R^9, R^{10}, R^{11} are independently H, C_1-C_{30} alkyl, C_3-C_{30} cycloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl, C_2-C_{30} alkynyl, C_1-C_{30} trihalogenoalkyl, C_1-C_{30}

alkylamino-(C_1-C_{30})alkyl, C_1-C_{30} dialkylamino(C_1-C_{30})-alkyl, amino-(C_1-C_{30})-alkyl, or



where R^{14}, R^{15}, R^{16} are independently H, halogen, C_1-C_{30} alkyl, C_3-C_{30} cycloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl or C_2-C_{30} alkynyl, or C_1-C_{30} trihalogenoalkyl, and m is 0 to 4,

each of these groups including or not heteroatom(s),

or salt or tautomeric form thereof.

13. (New) The method of claim 12, wherein the leukemia is selected from the group consisting of chronic myeloid leukemia, acute myeloid leukemia, acute nonlymphocytic leukemia, acute promyelocytic leukemia and myelodysplastic syndrome.

14. (New) The method of claim 12, wherein chronic myeloid leukemia is the leukemia to be treated.

15. (New) The method of claim 1 where the harringtonine is a harringtonine salt having the following formula



where A^- is

a mineral anion selected from the group consisting of chloride, sulfate, nitrate, and perchlorate, or

an organic ion selected from the group consisting of tartarate, malate, lactate, and citrate, and p is 1 or 2.

16. (New) The method of claim 1 where the harringtonine is a harringtonine salt having the following formula



where A^- is

a mineral anion selected from the group consisting of chloride, sulfate, nitrate, and perchlorate, or

an organic ion selected from the group consisting of tartarate, malate, lactate, and citrate, and p is 1 or 2.

17. (New) The method of claim 16 in which the acid which forms a salt of harringtonines is hydrochloric acid or tartaric acid.

18. (New) The method of claim 8 in which the nucleoside is cytosine arabinoside.

19. (New) The method of claim 9 in which the subcutaneous mode of administration is performed by bolus injection at one to four injections a day for at least one day.

20. (New) The method of claim 19, in which the subcutaneous mode of administration is performed by bolus injection at one to four injections a day for 28 days.

21. (New) A method of treating leukemia comprising administering to a patient in need of such treatment using a subcutaneous mode of administration a harringtonine having the formula



wherein:

- R^1 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or null and

  R^2 is H or OH, or R^1, R^2 form together -O-,

$R^3 = R^4 =$ OMe or R^3 and R^4 form together -OCH_2O-,

- n is 0 to 8,
- R^5 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or O-aryl,

Z = O, S, or NH, and

$R^8 =$ 

or Z-R^8 is $NR^{12}R^{13}$, R^{12} and R^{13} representing respectively R^9 and R^{10},

R^9, R^{10}, R^{11} are independently H, C_1-C_{30} alkyl, C_3-C_{30} cycloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl, C_2-C_{30} alkynyl, C_1-C_{30} trihalogenoalkyl, C_1-C_{30} alkylamino-(C_1-C_{30})alkyl, C_1-C_{30} dialkylamino(C_1-C_{30})-alkyl, amino-(C_1-C_{30})-alkyl, or



where R^{14}, R^{15}, R^{16} are independently H, halogen, C_1-C_{30} alkyl, C_3-C_{30} cycloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl or C_2-C_{30} alkynyl, or C_1-C_{30} trihalogenoalkyl, and m is 0 to 4,

each of these groups optionally including heteroatom(s),

or salt or tautomeric form thereof,

wherein said harringtonine is in a formulation in which

(i) the pH of the formulation is between 5.5 and 8.5,

(ii) the harringtonines are in solution or hydrophilic freeze-dried powder ready-to-reconstitute of buffered salt of homoharringtonine or harringtonine, and

(iii) the level of chromatographic purity of harringtonine is higher than 99.7%.

22. (New) The method of claim 11, wherein the additional antitumor agent is azadeoxycytidine (decitabine) or troxacytabine.

23. (New) The method of claim 12, wherein at least one additional antitumor agent is administered with the harringtonine.

24. (New) The method of claim 1, wherein the cancer to be treated is a lymphoma.

25. (New) The method of claim 1, wherein said patient is a human.

26. (New) The method of claim 1, wherein said patient is an animal.

27. (New) The method of claim 12 in which the harringtonine is a harringtonine salt having the following formula,



where A^- is

a mineral anion selected from the group consisting of chloride, sulfate, nitrate, and perchlorate, or

an organic ion selected from the group consisting of tartarate, malate, lactate, and citrate, and p is 1 or 2.